Skip to main content

HBV

5
Pipeline Programs
5
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Kite Pharma
Kite PharmaCA - El Segundo
2 programs
2
TAFPhase 31 trial
TAFPhase 31 trial
Active Trials
NCT02836249Completed181Est. Aug 2023
NCT02836236Completed155Est. Sep 2023
Golden Biotechnology
Golden BiotechnologyTaiwan - Taipei
1 program
1
AntroquinonolPhase 21 trial
Active Trials
NCT03625102Completed60Est. Jun 2023
F-star Therapeutics
F-star TherapeuticsUK - Cambridge
1 program
1
inarigivir soproxilPhase 21 trial
Active Trials
NCT03932513Terminated8Est. Dec 2019
Star Therapeutics
Star TherapeuticsCA - South SF
1 program
1
inarigivir soproxilPhase 2
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
nucleoside analogues or interferonN/A1 trial
Active Trials
NCT05965388Not Yet Recruiting5,000Est. Feb 2029

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Kite PharmaTAF
Kite PharmaTAF
F-star Therapeuticsinarigivir soproxil
Golden BiotechnologyAntroquinonol
UNION therapeuticsnucleoside analogues or interferon

Clinical Trials (5)

Total enrollment: 5,404 patients across 5 trials

NCT02836249Kite PharmaTAF

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Positive Hepatitis B (China)

Start: Jun 2015Est. completion: Aug 2023181 patients
Phase 3Completed
NCT02836236Kite PharmaTAF

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Negative Hepatitis B (China)

Start: Jun 2015Est. completion: Sep 2023155 patients
Phase 3Completed
NCT03932513F-star Therapeuticsinarigivir soproxil

Evaluating the Effects of Inarigivir on Immune Response and Viral Markers in Chronic Hepatitis B Patients

Start: Apr 2019Est. completion: Dec 20198 patients
Phase 2Terminated
NCT03625102Golden BiotechnologyAntroquinonol

A Randomized, Double-Blind Trial of Antroquinonol in Patients With Chronic Hepatitis B

Start: Aug 2018Est. completion: Jun 202360 patients
Phase 2Completed
NCT05965388UNION therapeuticsnucleoside analogues or interferon

Predictive Value of HBV pgRNA on Long-term Outcomes in Hepatitis B Patients Treated With Antiviral Therapy

Start: Dec 2023Est. completion: Feb 20295,000 patients
N/ANot Yet Recruiting

Related Jobs

Senior Therapeutic Specialist - Hepatitis B/D Hartford, CT

Gilead SciencesGilead Sciences
United States - Field; United States - Connecticut - Hartford; United States - Connecticut - Stamford (Field-Based)
1mo ago
$133K - $172K/yr

Brand Manager*in Hepatology (m/w/d)

GSKGSK
Munich - Office
1mo ago

Therapeutic Specialist - Hepatitis B/D - Minneapolis, MN

Gilead SciencesGilead Sciences
United States - Field
1mo ago
$115K - $149K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.